Scarica l'app Stockscreener
154.06
0.82%
1.26
Dopo l'orario di chiusura:
155.00
0.94
+0.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$152.80
Aprire:
$152.78
Volume 24 ore:
758.54K
Relative Volume:
0.79
Capitalizzazione di mercato:
$15.36B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
52.22
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
-0.60%
1M Prestazione:
+6.35%
6M Prestazione:
+23.85%
1 anno Prestazione:
+21.59%
Intervallo 1D:
$151.12
$155.55
Intervallo di 1 settimana:
$151.09
$156.69
Portata 52W:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
154.06 | 15.24B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
120.98 | 52.29B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.61 | 45.27B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 42.39B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.13 | 34.18B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
500.30 | 21.27B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
What analysts say about Neurocrine Biosciences Inc stockMomentum Trading Signals & Free Daily Top Stock Picks for All Investors - earlytimes.in
Hudson Bay Capital Management LP Has $9.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns - simplywall.st
Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Boone Capital Management LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX is Braidwell LP's 3rd Largest Position - MarketBeat
Ieq Capital LLC Buys 35,956 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Mizuho raises Neurocrine Bio. stock price target to $175 on Crenessity outlook - Investing.com India
Stifel Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Stifel Nicolaus Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Neurocrine Biosciences chief legal officer Lippoldt sells $698k in stock - Investing.com Canada
Neurocrine Bio. stock rating reiterated at Buy by TD Cowen - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $698,628.40 in Stock - MarketBeat
Neurocrine Biosciences Insider Sold Shares Worth $698,615, According to a Recent SEC Filing - marketscreener.com
Diadema Partners LP Has $11.82 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Amundi Has $28.36 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences to Host R&D Day on December 16 - cnhinews.com
Arrowstreet Capital Limited Partnership Acquires 58,562 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
RBC Capital Maintains Neurocrine Biosciences (NBIX) Outperform Recommendation - Nasdaq
RBC Capital Initiates Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $180 - 富途牛牛
Neurocrine Biosciences (NASDAQ:NBIX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Neurocrine Biosciences stock hits 52-week high at $157.88 By Investing.com - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $180.00 - MarketBeat
Neurocrine Biosciences stock hits 52-week high at $157.88 - Investing.com
RBC Raises Price Target on Neurocrine Biosciences to $180 From $160, Keeps Outperform Rating - marketscreener.com
Hood River Capital Management LLC Sells 79,626 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Bio. stock price target raised to $180 from $160 at RBC Capital - Investing.com
Neurocrine Biosciences (NBIX) valuation update after NBI-1070770 Phase 2 trial failure reshapes pipeline expectations - Sahm
Earnings Recap: How Neurocrine Biosciences Inc stock performs in weak economyWeekly Trade Report & High Accuracy Trade Alerts - moha.gov.vn
TD Cowen Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Growth Value: How MSPRO stock compares to industry benchmarksQuarterly Performance Summary & AI Powered Market Entry Strategies - BỘ NỘI VỤ
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Brown Advisory Inc. - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
TD Cowen Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level - Investor's Business Daily
Saturn V Capital Management LP Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Will Neurocrine Biosciences Inc. stock split again soonWeekly Loss Report & Free Fast Gain Swing Trade Alerts - Newser
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen By Investing.com - Investing.com South Africa
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen - Investing.com India
Why Neurocrine Biosciences Inc. (NB3) stock stays on buy listsPortfolio Gains Summary & High Accuracy Trade Signal Alerts - Newser
Dodge & Cox Increases Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
U.S. Tardive Dyskinesia Treatment Market to Reach USD 6417.43 - openPR.com
Will Neurocrine Biosciences Inc. (NB3) stock beat growth indexesOil Prices & Accurate Technical Buy Alerts - Newser
Is Neurocrine Biosciences Stock Built to Withstand a Pullback? - Trefis
Lyons (Neurocrine Biosciences director) sells $2.29m in NBIX stock - Investing.com
Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing - marketscreener.com
Dir Lyons Sells 15,000 ($2.3M) Of Neurocrine Biosciences Inc [NBIX] - TradingView
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockWeekly Trend Summary & Real-Time Buy Zone Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyDollar Strength & Growth Oriented Trade Recommendations - Newser
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):